Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-01-27

AUTHORS

Shailender Bhatia, Brendan Curti, Marc S Ernstoff, Michael Gordon, Elisabeth I Heath, Wilson H Miller, Igor Puzanov, David I Quinn, Thomas W Flaig, Peter VanVeldhuizen, Kelly Byrnes-Blake, Jeremy A Freeman, Rachel Bittner, Naomi Hunder, Sonia Souza, John A Thompson

ABSTRACT

BackgroundDespite the positive impact of targeted therapies on metastatic renal cell carcinoma (mRCC), durable responses are infrequent and an unmet need exists for novel therapies with distinct mechanisms of action. We investigated the combination of recombinant Interleukin 21 (IL-21), a cytokine with unique immunostimulatory properties, plus sorafenib, a VEGFR tyrosine kinase inhibitor.MethodsIn this phase 1/2 study, 52 mRCC patients received outpatient treatment with oral sorafenib 400 mg twice daily plus intravenous IL-21 (10–50 mcg/kg) on days 1–5 and 15–19 of each 7-week treatment course. The safety, antitumor activity, pharmacokinetic and pharmacodynamic effects of the combination were evaluated.ResultsIn phase 1 (n = 19), the maximum tolerated dose for IL-21 with the standard dose of sorafenib was determined to be 30 mcg/kg/day; grade 3 skin rash was the only dose-limiting toxicity. In phase 2, 33 previously-treated patients tolerated the combination therapy well with appropriate dose reductions; toxicities were mostly grade 1 or 2. The objective response rate was 21% and disease control rate was 82%. Two patients have durable responses that are ongoing, despite cessation of both IL-21 and sorafenib, at 41+ and 30+ months, respectively. The median progression-free survival in phase 2 was 5.6 months. The pharmacokinetic and pharmacodynamic properties of IL-21 appeared to be preserved in the presence of sorafenib.ConclusionIL-21 plus sorafenib has antitumor activity and acceptable safety in previously treated mRCC patients. IL-21 may represent a suitable immunotherapy in further exploration of combination strategies in mRCC.Trial registrationClinicalTrials.gov Identifier: NCT00389285 More... »

PAGES

2

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/2051-1426-2-2

DOI

http://dx.doi.org/10.1186/2051-1426-2-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1032036866

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24829759


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Medical Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Ave East, Mailstop G4-830, 98109-1023, Seattle, WA, USA", 
          "id": "http://www.grid.ac/institutes/grid.430269.a", 
          "name": [
            "University of Washington, Seattle, WA, USA", 
            "Division of Medical Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Ave East, Mailstop G4-830, 98109-1023, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bhatia", 
        "givenName": "Shailender", 
        "id": "sg:person.01034020517.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034020517.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Providence Portland Medical Center, Portland, OR, USA", 
          "id": "http://www.grid.ac/institutes/grid.240531.1", 
          "name": [
            "Providence Portland Medical Center, Portland, OR, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Curti", 
        "givenName": "Brendan", 
        "id": "sg:person.01155143760.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155143760.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA", 
          "id": "http://www.grid.ac/institutes/grid.413480.a", 
          "name": [
            "Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ernstoff", 
        "givenName": "Marc S", 
        "id": "sg:person.01115160302.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115160302.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pinnacle Oncology Hematology, Scottsdale, AZ, USA", 
          "id": "http://www.grid.ac/institutes/grid.492843.0", 
          "name": [
            "Pinnacle Oncology Hematology, Scottsdale, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gordon", 
        "givenName": "Michael", 
        "id": "sg:person.0713550751.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713550751.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA", 
          "id": "http://www.grid.ac/institutes/grid.477517.7", 
          "name": [
            "Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heath", 
        "givenName": "Elisabeth I", 
        "id": "sg:person.01136603555.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136603555.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Quebec", 
          "id": "http://www.grid.ac/institutes/grid.14709.3b", 
          "name": [
            "Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Quebec"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miller", 
        "givenName": "Wilson H", 
        "id": "sg:person.0707336465.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0707336465.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA", 
          "id": "http://www.grid.ac/institutes/grid.412807.8", 
          "name": [
            "Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Puzanov", 
        "givenName": "Igor", 
        "id": "sg:person.0640153517.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640153517.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quinn", 
        "givenName": "David I", 
        "id": "sg:person.01013134010.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Colorado Cancer Center, Aurora, CO, USA", 
          "id": "http://www.grid.ac/institutes/grid.499234.1", 
          "name": [
            "University of Colorado Cancer Center, Aurora, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Flaig", 
        "givenName": "Thomas W", 
        "id": "sg:person.01231570121.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231570121.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Kansas Medical Center, Westwood, KS, USA", 
          "id": "http://www.grid.ac/institutes/grid.412016.0", 
          "name": [
            "University of Kansas Medical Center, Westwood, KS, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "VanVeldhuizen", 
        "givenName": "Peter", 
        "id": "sg:person.0714037171.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714037171.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Formerly of ZymoGenetics (Bristol-Myers Squibb), Seattle, WA, USA", 
          "id": "http://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "Formerly of ZymoGenetics (Bristol-Myers Squibb), Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Byrnes-Blake", 
        "givenName": "Kelly", 
        "id": "sg:person.0630753011.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630753011.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Formerly of ZymoGenetics (Bristol-Myers Squibb), Seattle, WA, USA", 
          "id": "http://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "Formerly of ZymoGenetics (Bristol-Myers Squibb), Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Freeman", 
        "givenName": "Jeremy A", 
        "id": "sg:person.01175656411.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175656411.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "ZymoGenetics (Bristol-Myers Squibb), Seattle, WA, USA", 
          "id": "http://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "ZymoGenetics (Bristol-Myers Squibb), Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bittner", 
        "givenName": "Rachel", 
        "id": "sg:person.0646752430.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646752430.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Formerly of ZymoGenetics (Bristol-Myers Squibb), Seattle, WA, USA", 
          "id": "http://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "Formerly of ZymoGenetics (Bristol-Myers Squibb), Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hunder", 
        "givenName": "Naomi", 
        "id": "sg:person.01367504225.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367504225.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Formerly of ZymoGenetics (Bristol-Myers Squibb), Seattle, WA, USA", 
          "id": "http://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "Formerly of ZymoGenetics (Bristol-Myers Squibb), Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Souza", 
        "givenName": "Sonia", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington, Seattle, WA, USA", 
          "id": "http://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "University of Washington, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thompson", 
        "givenName": "John A", 
        "id": "sg:person.013367762644.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013367762644.21"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00262-007-0285-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042885946", 
          "https://doi.org/10.1007/s00262-007-0285-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35040504", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027439653", 
          "https://doi.org/10.1038/35040504"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2482", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010403574", 
          "https://doi.org/10.1038/nrd2482"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00345-011-0673-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016728204", 
          "https://doi.org/10.1007/s00345-011-0673-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00262-008-0479-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000717389", 
          "https://doi.org/10.1007/s00262-008-0479-4"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-01-27", 
    "datePublishedReg": "2014-01-27", 
    "description": "BackgroundDespite the positive impact of targeted therapies on metastatic renal cell carcinoma (mRCC), durable responses are infrequent and an unmet need exists for novel therapies with distinct mechanisms of action. We investigated the combination of recombinant Interleukin 21 (IL-21), a cytokine with unique immunostimulatory properties, plus sorafenib, a VEGFR tyrosine kinase inhibitor.MethodsIn this phase 1/2 study, 52 mRCC patients received outpatient treatment with oral sorafenib 400\u00a0mg twice daily plus intravenous IL-21 (10\u201350 mcg/kg) on days 1\u20135 and 15\u201319 of each 7-week treatment course. The safety, antitumor activity, pharmacokinetic and pharmacodynamic effects of the combination were evaluated.ResultsIn phase 1 (n\u2009=\u200919), the maximum tolerated dose for IL-21 with the standard dose of sorafenib was determined to be 30 mcg/kg/day; grade 3 skin rash was the only dose-limiting toxicity. In phase 2, 33 previously-treated patients tolerated the combination therapy well with appropriate dose reductions; toxicities were mostly grade 1 or 2. The objective response rate was 21% and disease control rate was 82%. Two patients have durable responses that are ongoing, despite cessation of both IL-21 and sorafenib, at 41+ and 30+ months, respectively. The median progression-free survival in phase 2 was 5.6\u00a0months. The pharmacokinetic and pharmacodynamic properties of IL-21 appeared to be preserved in the presence of sorafenib.ConclusionIL-21 plus sorafenib has antitumor activity and acceptable safety in previously treated mRCC patients. IL-21 may represent a suitable immunotherapy in further exploration of combination strategies in mRCC.Trial registrationClinicalTrials.gov Identifier: NCT00389285", 
    "genre": "article", 
    "id": "sg:pub.10.1186/2051-1426-2-2", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "publisher": "BMJ", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "2"
      }
    ], 
    "keywords": [
      "metastatic renal cell carcinoma", 
      "phase 1/2 study", 
      "IL-21", 
      "renal cell carcinoma", 
      "Recombinant interleukin-21", 
      "mRCC patients", 
      "durable responses", 
      "interleukin-21", 
      "cell carcinoma", 
      "grade 3 skin rash", 
      "only dose-limiting toxicity", 
      "median progression-free survival", 
      "VEGFR tyrosine kinase inhibitors", 
      "oral sorafenib 400", 
      "antitumor activity", 
      "objective response rate", 
      "disease control rate", 
      "progression-free survival", 
      "dose-limiting toxicity", 
      "appropriate dose reduction", 
      "ResultsIn phase 1", 
      "tyrosine kinase inhibitors", 
      "unmet need exists", 
      "presence of sorafenib", 
      "phase 2", 
      "sorafenib 400", 
      "suitable immunotherapy", 
      "skin rash", 
      "treatment course", 
      "pharmacodynamic effects", 
      "standard dose", 
      "combination therapy", 
      "control rate", 
      "outpatient treatment", 
      "acceptable safety", 
      "mcg/", 
      "novel therapies", 
      "dose reduction", 
      "pharmacodynamic properties", 
      "day 1", 
      "immunostimulatory properties", 
      "response rate", 
      "sorafenib", 
      "patients", 
      "grade 1", 
      "kinase inhibitors", 
      "therapy", 
      "carcinoma", 
      "need exists", 
      "combination strategies", 
      "phase 1", 
      "dose", 
      "months", 
      "distinct mechanisms", 
      "toxicity", 
      "further exploration", 
      "safety", 
      "rash", 
      "immunotherapy", 
      "cytokines", 
      "BackgroundDespite", 
      "MethodsIn", 
      "response", 
      "cessation", 
      "survival", 
      "treatment", 
      "inhibitors", 
      "activity", 
      "study", 
      "days", 
      "rate", 
      "course", 
      "combination", 
      "action", 
      "positive impact", 
      "reduction", 
      "effect", 
      "presence", 
      "mechanism", 
      "strategies", 
      "impact", 
      "exists", 
      "identifiers", 
      "exploration", 
      "maximum", 
      "properties"
    ], 
    "name": "Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study", 
    "pagination": "2", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1032036866"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/2051-1426-2-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24829759"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/2051-1426-2-2", 
      "https://app.dimensions.ai/details/publication/pub.1032036866"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:39", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_626.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/2051-1426-2-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/2051-1426-2-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/2051-1426-2-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/2051-1426-2-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/2051-1426-2-2'


 

This table displays all metadata directly associated to this object as RDF triples.

306 TRIPLES      21 PREDICATES      116 URIs      103 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/2051-1426-2-2 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N7ca3612f62524c3f8d58934fca0a0b63
4 schema:citation sg:pub.10.1007/s00262-007-0285-4
5 sg:pub.10.1007/s00262-008-0479-4
6 sg:pub.10.1007/s00345-011-0673-4
7 sg:pub.10.1038/35040504
8 sg:pub.10.1038/nrd2482
9 schema:datePublished 2014-01-27
10 schema:datePublishedReg 2014-01-27
11 schema:description BackgroundDespite the positive impact of targeted therapies on metastatic renal cell carcinoma (mRCC), durable responses are infrequent and an unmet need exists for novel therapies with distinct mechanisms of action. We investigated the combination of recombinant Interleukin 21 (IL-21), a cytokine with unique immunostimulatory properties, plus sorafenib, a VEGFR tyrosine kinase inhibitor.MethodsIn this phase 1/2 study, 52 mRCC patients received outpatient treatment with oral sorafenib 400 mg twice daily plus intravenous IL-21 (10–50 mcg/kg) on days 1–5 and 15–19 of each 7-week treatment course. The safety, antitumor activity, pharmacokinetic and pharmacodynamic effects of the combination were evaluated.ResultsIn phase 1 (n = 19), the maximum tolerated dose for IL-21 with the standard dose of sorafenib was determined to be 30 mcg/kg/day; grade 3 skin rash was the only dose-limiting toxicity. In phase 2, 33 previously-treated patients tolerated the combination therapy well with appropriate dose reductions; toxicities were mostly grade 1 or 2. The objective response rate was 21% and disease control rate was 82%. Two patients have durable responses that are ongoing, despite cessation of both IL-21 and sorafenib, at 41+ and 30+ months, respectively. The median progression-free survival in phase 2 was 5.6 months. The pharmacokinetic and pharmacodynamic properties of IL-21 appeared to be preserved in the presence of sorafenib.ConclusionIL-21 plus sorafenib has antitumor activity and acceptable safety in previously treated mRCC patients. IL-21 may represent a suitable immunotherapy in further exploration of combination strategies in mRCC.Trial registrationClinicalTrials.gov Identifier: NCT00389285
12 schema:genre article
13 schema:isAccessibleForFree true
14 schema:isPartOf N8596ec48d0e14765ac29d90d444aab7f
15 N88719df9b3ad4e068015ea9ef20498c3
16 sg:journal.1049249
17 schema:keywords BackgroundDespite
18 IL-21
19 MethodsIn
20 Recombinant interleukin-21
21 ResultsIn phase 1
22 VEGFR tyrosine kinase inhibitors
23 acceptable safety
24 action
25 activity
26 antitumor activity
27 appropriate dose reduction
28 carcinoma
29 cell carcinoma
30 cessation
31 combination
32 combination strategies
33 combination therapy
34 control rate
35 course
36 cytokines
37 day 1
38 days
39 disease control rate
40 distinct mechanisms
41 dose
42 dose reduction
43 dose-limiting toxicity
44 durable responses
45 effect
46 exists
47 exploration
48 further exploration
49 grade 1
50 grade 3 skin rash
51 identifiers
52 immunostimulatory properties
53 immunotherapy
54 impact
55 inhibitors
56 interleukin-21
57 kinase inhibitors
58 mRCC patients
59 maximum
60 mcg/
61 mechanism
62 median progression-free survival
63 metastatic renal cell carcinoma
64 months
65 need exists
66 novel therapies
67 objective response rate
68 only dose-limiting toxicity
69 oral sorafenib 400
70 outpatient treatment
71 patients
72 pharmacodynamic effects
73 pharmacodynamic properties
74 phase 1
75 phase 1/2 study
76 phase 2
77 positive impact
78 presence
79 presence of sorafenib
80 progression-free survival
81 properties
82 rash
83 rate
84 reduction
85 renal cell carcinoma
86 response
87 response rate
88 safety
89 skin rash
90 sorafenib
91 sorafenib 400
92 standard dose
93 strategies
94 study
95 suitable immunotherapy
96 survival
97 therapy
98 toxicity
99 treatment
100 treatment course
101 tyrosine kinase inhibitors
102 unmet need exists
103 schema:name Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
104 schema:pagination 2
105 schema:productId N35a326ff993d40a493fcd314d835a52f
106 N4b3682049aea4a089605bcf8dffc44af
107 N55d0b3fff09a4be88a5d31e38b943b83
108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032036866
109 https://doi.org/10.1186/2051-1426-2-2
110 schema:sdDatePublished 2022-10-01T06:39
111 schema:sdLicense https://scigraph.springernature.com/explorer/license/
112 schema:sdPublisher Nbc9a3644a4dc4e2aae08951993160700
113 schema:url https://doi.org/10.1186/2051-1426-2-2
114 sgo:license sg:explorer/license/
115 sgo:sdDataset articles
116 rdf:type schema:ScholarlyArticle
117 N1e2d7326e88e4720bbd18c53519d4b2e rdf:first sg:person.01136603555.42
118 rdf:rest N6cdc1385c71d4fb68139957fd22ff15f
119 N2c30ef40b54a42c7a8d14f1d14e28f6f rdf:first sg:person.01155143760.43
120 rdf:rest N589559d21c6d4649a9f554ca572b5756
121 N35a326ff993d40a493fcd314d835a52f schema:name pubmed_id
122 schema:value 24829759
123 rdf:type schema:PropertyValue
124 N4b3682049aea4a089605bcf8dffc44af schema:name doi
125 schema:value 10.1186/2051-1426-2-2
126 rdf:type schema:PropertyValue
127 N55d0b3fff09a4be88a5d31e38b943b83 schema:name dimensions_id
128 schema:value pub.1032036866
129 rdf:type schema:PropertyValue
130 N589559d21c6d4649a9f554ca572b5756 rdf:first sg:person.01115160302.45
131 rdf:rest Nd9f22228e1a346afab4f6a5641ff3bfc
132 N5f07ed9237ad41d7ad66bf0092491a2f schema:affiliation grid-institutes:grid.419971.3
133 schema:familyName Souza
134 schema:givenName Sonia
135 rdf:type schema:Person
136 N65e466e27e8a4d609d3ad21fb33616b7 rdf:first sg:person.0646752430.27
137 rdf:rest Nde5a8f78834d490ba6bc9d7ddc6c9413
138 N6a893607aec5446aa63ed7e9bae1eb32 rdf:first N5f07ed9237ad41d7ad66bf0092491a2f
139 rdf:rest N6c6d93fe86ba4380a88852f25a1dabe4
140 N6c6d93fe86ba4380a88852f25a1dabe4 rdf:first sg:person.013367762644.21
141 rdf:rest rdf:nil
142 N6cdc1385c71d4fb68139957fd22ff15f rdf:first sg:person.0707336465.30
143 rdf:rest N91ac84ed018b49dfa3431415cb8ade78
144 N6efbb1ddf51f4cb6b46b3273626a50fc rdf:first sg:person.0630753011.73
145 rdf:rest N92129e97a5814b50ae8b4c83f0619d2b
146 N7ca3612f62524c3f8d58934fca0a0b63 rdf:first sg:person.01034020517.30
147 rdf:rest N2c30ef40b54a42c7a8d14f1d14e28f6f
148 N8596ec48d0e14765ac29d90d444aab7f schema:issueNumber 1
149 rdf:type schema:PublicationIssue
150 N88719df9b3ad4e068015ea9ef20498c3 schema:volumeNumber 2
151 rdf:type schema:PublicationVolume
152 N91ac84ed018b49dfa3431415cb8ade78 rdf:first sg:person.0640153517.24
153 rdf:rest Nb2a5c3eb03cc4fa19ace70d0b6752384
154 N92129e97a5814b50ae8b4c83f0619d2b rdf:first sg:person.01175656411.85
155 rdf:rest N65e466e27e8a4d609d3ad21fb33616b7
156 N95ab34afd8484a3db3d4488ee04aa31f rdf:first sg:person.0714037171.20
157 rdf:rest N6efbb1ddf51f4cb6b46b3273626a50fc
158 Nb2a5c3eb03cc4fa19ace70d0b6752384 rdf:first sg:person.01013134010.15
159 rdf:rest Ndcd0baccff6247d783f54610626d77eb
160 Nbc9a3644a4dc4e2aae08951993160700 schema:name Springer Nature - SN SciGraph project
161 rdf:type schema:Organization
162 Nd9f22228e1a346afab4f6a5641ff3bfc rdf:first sg:person.0713550751.04
163 rdf:rest N1e2d7326e88e4720bbd18c53519d4b2e
164 Ndcd0baccff6247d783f54610626d77eb rdf:first sg:person.01231570121.99
165 rdf:rest N95ab34afd8484a3db3d4488ee04aa31f
166 Nde5a8f78834d490ba6bc9d7ddc6c9413 rdf:first sg:person.01367504225.19
167 rdf:rest N6a893607aec5446aa63ed7e9bae1eb32
168 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
169 schema:name Medical and Health Sciences
170 rdf:type schema:DefinedTerm
171 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
172 schema:name Clinical Sciences
173 rdf:type schema:DefinedTerm
174 sg:journal.1049249 schema:issn 2051-1426
175 schema:name Journal for ImmunoTherapy of Cancer
176 schema:publisher BMJ
177 rdf:type schema:Periodical
178 sg:person.01013134010.15 schema:affiliation grid-institutes:grid.42505.36
179 schema:familyName Quinn
180 schema:givenName David I
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15
182 rdf:type schema:Person
183 sg:person.01034020517.30 schema:affiliation grid-institutes:grid.430269.a
184 schema:familyName Bhatia
185 schema:givenName Shailender
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034020517.30
187 rdf:type schema:Person
188 sg:person.01115160302.45 schema:affiliation grid-institutes:grid.413480.a
189 schema:familyName Ernstoff
190 schema:givenName Marc S
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115160302.45
192 rdf:type schema:Person
193 sg:person.01136603555.42 schema:affiliation grid-institutes:grid.477517.7
194 schema:familyName Heath
195 schema:givenName Elisabeth I
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136603555.42
197 rdf:type schema:Person
198 sg:person.01155143760.43 schema:affiliation grid-institutes:grid.240531.1
199 schema:familyName Curti
200 schema:givenName Brendan
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155143760.43
202 rdf:type schema:Person
203 sg:person.01175656411.85 schema:affiliation grid-institutes:grid.419971.3
204 schema:familyName Freeman
205 schema:givenName Jeremy A
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175656411.85
207 rdf:type schema:Person
208 sg:person.01231570121.99 schema:affiliation grid-institutes:grid.499234.1
209 schema:familyName Flaig
210 schema:givenName Thomas W
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231570121.99
212 rdf:type schema:Person
213 sg:person.013367762644.21 schema:affiliation grid-institutes:grid.34477.33
214 schema:familyName Thompson
215 schema:givenName John A
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013367762644.21
217 rdf:type schema:Person
218 sg:person.01367504225.19 schema:affiliation grid-institutes:grid.419971.3
219 schema:familyName Hunder
220 schema:givenName Naomi
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367504225.19
222 rdf:type schema:Person
223 sg:person.0630753011.73 schema:affiliation grid-institutes:grid.419971.3
224 schema:familyName Byrnes-Blake
225 schema:givenName Kelly
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630753011.73
227 rdf:type schema:Person
228 sg:person.0640153517.24 schema:affiliation grid-institutes:grid.412807.8
229 schema:familyName Puzanov
230 schema:givenName Igor
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640153517.24
232 rdf:type schema:Person
233 sg:person.0646752430.27 schema:affiliation grid-institutes:grid.419971.3
234 schema:familyName Bittner
235 schema:givenName Rachel
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646752430.27
237 rdf:type schema:Person
238 sg:person.0707336465.30 schema:affiliation grid-institutes:grid.14709.3b
239 schema:familyName Miller
240 schema:givenName Wilson H
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0707336465.30
242 rdf:type schema:Person
243 sg:person.0713550751.04 schema:affiliation grid-institutes:grid.492843.0
244 schema:familyName Gordon
245 schema:givenName Michael
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713550751.04
247 rdf:type schema:Person
248 sg:person.0714037171.20 schema:affiliation grid-institutes:grid.412016.0
249 schema:familyName VanVeldhuizen
250 schema:givenName Peter
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714037171.20
252 rdf:type schema:Person
253 sg:pub.10.1007/s00262-007-0285-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042885946
254 https://doi.org/10.1007/s00262-007-0285-4
255 rdf:type schema:CreativeWork
256 sg:pub.10.1007/s00262-008-0479-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000717389
257 https://doi.org/10.1007/s00262-008-0479-4
258 rdf:type schema:CreativeWork
259 sg:pub.10.1007/s00345-011-0673-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016728204
260 https://doi.org/10.1007/s00345-011-0673-4
261 rdf:type schema:CreativeWork
262 sg:pub.10.1038/35040504 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027439653
263 https://doi.org/10.1038/35040504
264 rdf:type schema:CreativeWork
265 sg:pub.10.1038/nrd2482 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010403574
266 https://doi.org/10.1038/nrd2482
267 rdf:type schema:CreativeWork
268 grid-institutes:grid.14709.3b schema:alternateName Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Quebec
269 schema:name Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Quebec
270 rdf:type schema:Organization
271 grid-institutes:grid.240531.1 schema:alternateName Providence Portland Medical Center, Portland, OR, USA
272 schema:name Providence Portland Medical Center, Portland, OR, USA
273 rdf:type schema:Organization
274 grid-institutes:grid.34477.33 schema:alternateName University of Washington, Seattle, WA, USA
275 schema:name University of Washington, Seattle, WA, USA
276 rdf:type schema:Organization
277 grid-institutes:grid.412016.0 schema:alternateName University of Kansas Medical Center, Westwood, KS, USA
278 schema:name University of Kansas Medical Center, Westwood, KS, USA
279 rdf:type schema:Organization
280 grid-institutes:grid.412807.8 schema:alternateName Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA
281 schema:name Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA
282 rdf:type schema:Organization
283 grid-institutes:grid.413480.a schema:alternateName Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
284 schema:name Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
285 rdf:type schema:Organization
286 grid-institutes:grid.419971.3 schema:alternateName Formerly of ZymoGenetics (Bristol-Myers Squibb), Seattle, WA, USA
287 ZymoGenetics (Bristol-Myers Squibb), Seattle, WA, USA
288 schema:name Formerly of ZymoGenetics (Bristol-Myers Squibb), Seattle, WA, USA
289 ZymoGenetics (Bristol-Myers Squibb), Seattle, WA, USA
290 rdf:type schema:Organization
291 grid-institutes:grid.42505.36 schema:alternateName Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
292 schema:name Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
293 rdf:type schema:Organization
294 grid-institutes:grid.430269.a schema:alternateName Division of Medical Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Ave East, Mailstop G4-830, 98109-1023, Seattle, WA, USA
295 schema:name Division of Medical Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Ave East, Mailstop G4-830, 98109-1023, Seattle, WA, USA
296 University of Washington, Seattle, WA, USA
297 rdf:type schema:Organization
298 grid-institutes:grid.477517.7 schema:alternateName Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
299 schema:name Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
300 rdf:type schema:Organization
301 grid-institutes:grid.492843.0 schema:alternateName Pinnacle Oncology Hematology, Scottsdale, AZ, USA
302 schema:name Pinnacle Oncology Hematology, Scottsdale, AZ, USA
303 rdf:type schema:Organization
304 grid-institutes:grid.499234.1 schema:alternateName University of Colorado Cancer Center, Aurora, CO, USA
305 schema:name University of Colorado Cancer Center, Aurora, CO, USA
306 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...